K&L Gates Advises StemCyte On US$14 Million IPO On Taiwan Stock Exchange

At K&L Gates, we foster an inclusive and collaborative environment across our fully integrated global platform that enables us to diligently combine the knowledge and expertise of our lawyers and policy professionals to create teams that provide exceptional client solutions. With offices worldwide, we represent leading global corporations in every major industry, capital markets participants, and ambitious middle-market and emerging growth companies. Our lawyers also serve public sector entities, educational institutions, philanthropic organizations, and individuals. We are leaders in legal issues related to industries critical to the economies of both the developed and developing worlds—including technology, manufacturing, financial services, healthcare, energy, and more.

Explore Firm Details

Global law firm K&L Gates advised StemCyte International, Ltd. on its US$14 million initial public offering and primary listing on the Taiwan Stock Exchange.

United States

Global law firm K&L Gates advised StemCyte International, Ltd. on its US$14 million initial public offering and primary listing on the Taiwan Stock Exchange. The capital raise was completed through the issuance of 22.23 million new shares.

Established in 2013, StemCyte International, Ltd. is a leading provider of cord blood banking and stem cell-related services, supporting medical research and therapeutic applications worldwide.

The Corporate team advising StemCyte on the listing was led by Taipei partners Cheryl Hsieh and Billy Chen, with support from Palo Alto partner Kevin Cao.

Contributor

Explore Firm Details

See More Popular Content From